138 related articles for article (PubMed ID: 17048958)
1. Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.
Freitas RF; Galembeck SE
J Phys Chem B; 2006 Oct; 110(42):21287-98. PubMed ID: 17048958
[TBL] [Abstract][Full Text] [Related]
2. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
4. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
5. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
[TBL] [Abstract][Full Text] [Related]
6. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mitchell ML; Son JC; Lee IY; Lee CK; Kim HS; Guo H; Wang J; Hayes J; Wang M; Paul A; Lansdon EB; Chen JM; Eisenberg G; Geleziunas R; Xu L; Kim CU
Bioorg Med Chem Lett; 2010 Mar; 20(5):1585-8. PubMed ID: 20137928
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
8. The search for potent, small molecule NNRTIs: A review.
Prajapati DG; Ramajayam R; Yadav MR; Giridhar R
Bioorg Med Chem; 2009 Aug; 17(16):5744-62. PubMed ID: 19632850
[TBL] [Abstract][Full Text] [Related]
9. Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.
Saparpakorn P; Hannongbua S; Rognan D
SAR QSAR Environ Res; 2006 Apr; 17(2):183-94. PubMed ID: 16644557
[TBL] [Abstract][Full Text] [Related]
10. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
11. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
12. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
13. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
[TBL] [Abstract][Full Text] [Related]
14. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
He X; Mei Y; Xiang Y; Zhang DW; Zhang JZ
Proteins; 2005 Nov; 61(2):423-32. PubMed ID: 16114038
[TBL] [Abstract][Full Text] [Related]
15. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
Treesuwan W; Hannongbua S
J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
[TBL] [Abstract][Full Text] [Related]
16. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
[TBL] [Abstract][Full Text] [Related]
17. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
Ren J; Esnouf RM; Hopkins AL; Warren J; Balzarini J; Stuart DI; Stammers DK
Biochemistry; 1998 Oct; 37(41):14394-403. PubMed ID: 9772165
[TBL] [Abstract][Full Text] [Related]
19. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
20. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]